Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2013

View Archived Issues

ADAM10: potential target and genetic marker for late-onset AD

Discovery of a broad-genotype inhibitor of HCV replication

AllaChem completes phase I study of AV-4025

Hasselt University and Inova Diagnostics collaborate on biomarkers for RA

AstraZeneca selects miRNA oncology target under alliance with Regulus Therapeutics

STADA in-licenses approved biosimilar from Apotex

Santaris resumes full ownership of LNA programs licensed to Enzon

BELLUS Health and AmorChem sign co-development agreement for AL amyloidosis

BioTime discloses interim results from safety study of Renevia

Phase I/II trial of vosaroxin in myelodysplastic syndrome begins

Sophiris begins dosing in PLUS-1 phase III trial of PRX-302

Etanercept biosimilar product meets primary endpoint in pivotal study

Updated clinical data on nintedanib reported

Crown Bioscience describes patient-derived xenografts for testing CBI-3103

Bristol-Myers Squibb reports developments of third quarter 2013

University of South Florida discloses new myricanol derivatives

French team presents novel diagnostics for Alzheimer's disease

Novartis reports progress during third quarter 2013

Polish researchers patent new bacterial efflux pump inhibitors

Researchers at Apac Pharmaceutical synthesize novel agents for arthritis

Pharmacodynamic activity seen for AMG-811 in patients with SLE

Janssen Pharmaceutica divulges new CCR2 receptor antagonists

Stemline Therapeutics to accelerate development of SL-401 in hematologic cancers

Cara Therapeutics reports results from phase II trial of CR-845

Novel osteoporosis mouse models carry human RANKL gene

OncoMed Pharmaceuticals begins phase Ib trial of vantictumab with paclitaxel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...